Skip to main content

Advertisement

Table 1 Baseline Patient Characteristics and Baseline Health Related Quality-of-Lifea

From: Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)

   Docetaxel + Placebo (n = 489) Docetaxel + Astrasentan (n = 489)
Patient Characteristic Categories N (%) N (%)
Age: median (range)   69.6 (43.2–89.1) 69.4 (40.8–92.0)
Hispanic ethnicity Yes 20 (4.1%) 20 (4.1%)
Race White 397 (83.6%) 399 (83.3%)
Black 64 (13.5%) 72 (15.0%)
Asian 12 (2.5%) 6 (1.3%)
Pacific Islander 2 (0.4%) 3 (0.6%)
Native 1 (0.2%) 1 (0.2%)
Unknown 14 10
Performance status 2 or 3 Yes 39 (8.0%) 35 (7.2%)
Baseline progression type Measurable or evaluable 390 (79.8%) 402 (82.2%)
Extraskeletal metastases Yes 272 (55.6%) 281 (57.5%)
Prior Prostatectomy Yes 142 (29.0%) 165 (33.7%)
Gleason score 5–6 48 (10.3%) 52 (11.1%)
7 133 (28.7%) 138 (29.5%)
8–10 272 (58.6%) 271 (57.9%)
Missing 25 21
Pain Medication (worst) 0 – None 14 (4.4%) 18 (5.6%)
1 – Non-narcotic 116 (36.7%) 118 (36.5%)
2 – Weak opioid 97 (30.7%) 90 (27.9%)
3 – Strong opioid 89 (28.2%) 97 (30.0%)
Missing 173 166
Health Related QOL Categories N Mean SD N Mean SD
Brief Pain Inventory Worst pain 488 3.4 2.8 489 3.5 3.0
Worst pain, baseline + 4 week average 434 2.8 2.3 440 2.7 2.4
Pain interference 486 2.4 2.5 487 2.5 2.6
Pain interference, baseline + 4 week average 428 2.1 2.2 437 1.9 2.0
SF-36b Energy/vitality 487 48.2 23.3 487 48.3 24.1
Energy/vitality, baseline + 4 week average 435 49.5 20.7 437 51.7 21.0
FACT-Pc Trial outcome index 487 67.5 17.4 484 67.5 17.9
FACT-G total score 487 77.2 15.7 486 77.7 16.5
FACT-P total score 487 106.5 22.0 483 107.0 23.0
EORTC QLQ-C30d Global quality of life score 483 63.7 22.7 480 63.6 22.6
  1. aPercentages shown among those with known date only
  2. bMedical Outcomes Study 36 Item Short Form Health Survey
  3. cFunction Assessment of Cancer Therapy – Prostate Cancer
  4. dEuropean Organisation for Research and Treatment of Cancer – Quality of Life Questionnaire